Patents by Inventor Doug Shytle

Doug Shytle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Flavonoid treatment of glycogen synthase kinase-based disease
    Patent number: 8802638
    Abstract: The flavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin 1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. These findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association. In addition, Tg2576 mice treated with diosmin, a glycoside of a flavone structurally and functionally similar to luteolin (diosmetin), displayed significantly reduced A? pathology as well.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 12, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
  • Treatment of glycogen synthase kinase-based disease
    Patent number: 8778986
    Abstract: The bioflavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: July 15, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
  • Modulation of Microglial by Nicotinic Medications
    Publication number: 20060223790
    Abstract: A method of treating a subject suffering from a neurodegenerative disease by modulating microglial activation with a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor.
    Type: Application
    Filed: April 26, 2006
    Publication date: October 5, 2006
    Applicant: University of South Florida
    Inventors: Doug Shytle, Jun Tan, Francisco Fernandez
  • Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
    Publication number: 20060142180
    Abstract: Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as those chosen from the group consisting of acetycholine, nicotine, choline, galantamine, cytisine, GTS-21, or derivatives thereof, wherein the target cell is a microglia is provided.
    Type: Application
    Filed: February 7, 2006
    Publication date: June 29, 2006
    Inventors: Doug Shytle, Jun Tah, Paul Sanberg